Literature DB >> 27799206

Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

A Espinel-Ingroff1, M Arendrup2, E Cantón3, S Cordoba4, E Dannaoui5, J García-Rodríguez6, G M Gonzalez7, N P Govender8, E Martin-Mazuelos9, M Lackner10, C Lass-Flörl10, M J Linares Sicilia11, M A Rodriguez-Iglesias12, T Pelaez13, R K Shields14, G Garcia-Effron15, J Guinea16, M Sanguinetti17, J Turnidge18.   

Abstract

Method-dependent Etest epidemiological cutoff values (ECVs) are not available for susceptibility testing of either Candida or Aspergillus species with amphotericin B or echinocandins. In addition, reference caspofungin MICs for Candida spp. are unreliable. Candida and Aspergillus species wild-type (WT) Etest MIC distributions (microorganisms in a species-drug combination with no detectable phenotypic resistance) were established for 4,341 Candida albicans, 113 C. dubliniensis, 1,683 C. glabrata species complex (SC), 709 C. krusei, 767 C. parapsilosis SC, 796 C. tropicalis, 1,637 Aspergillus fumigatus SC, 238 A. flavus SC, 321 A. niger SC, and 247 A. terreus SC isolates. Etest MICs from 15 laboratories (in Argentina, Europe, Mexico, South Africa, and the United States) were pooled to establish Etest ECVs. Anidulafungin, caspofungin, micafungin, and amphotericin B ECVs (in micrograms per milliliter) encompassing ≥97.5% of the statistically modeled population were 0.016, 0.5, 0.03, and 1 for C. albicans; 0.03, 1, 0.03, and 2 for C. glabrata SC; 0.06, 1, 0.25, and 4 for C. krusei; 8, 4, 2, and 2 for C. parapsilosis SC; and 0.03, 1, 0.12, and 2 for C. tropicalis The amphotericin B ECV was 0.25 μg/ml for C. dubliniensis and 2, 8, 2, and 16 μg/ml for the complexes of A. fumigatus, A. flavus, A. niger, and A. terreus, respectively. While anidulafungin Etest ECVs classified 92% of the Candida fks mutants evaluated as non-WT, the performance was lower for caspofungin (75%) and micafungin (84%) cutoffs. Finally, although anidulafungin (as an echinocandin surrogate susceptibility marker) and amphotericin B ECVs should identify Candida and Aspergillus isolates with reduced susceptibility to these agents using the Etest, these ECVs will not categorize a fungal isolate as susceptible or resistant, as breakpoints do.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  ECVs; Etest ECVs; Etest MICs Aspergillus; Etest MICs Candida; WT isolates; amphotericin B resistance; antifungal resistance; echinocandin resistance; non-WT; susceptibility marker

Mesh:

Substances:

Year:  2016        PMID: 27799206      PMCID: PMC5192158          DOI: 10.1128/AAC.01792-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Authors:  M C Arendrup; J Meletiadis; J W Mouton; J Guinea; M Cuenca-Estrella; K Lagrou; S J Howard
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

4.  EUCAST technical note on Amphotericin B.

Authors:  C Lass-Flörl; M C Arendrup; J-L Rodriguez-Tudela; M Cuenca-Estrella; P Donnelly; W Hope
Journal:  Clin Microbiol Infect       Date:  2011-10-19       Impact factor: 8.067

5.  Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates.

Authors:  Ana Espinel-Ingroff; Emilia Cantón; Teresa Pelaez; Javier Pemán
Journal:  Diagn Microbiol Infect Dis       Date:  2011-05       Impact factor: 2.803

6.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

7.  Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

Authors:  Jesús Guinea; Óscar Zaragoza; Pilar Escribano; Estrella Martín-Mazuelos; Javier Pemán; Ferrán Sánchez-Reus; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

8.  Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.

Authors:  Maiken Cavling Arendrup; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

Review 9.  Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope
Journal:  Drug Resist Updat       Date:  2014-01-27       Impact factor: 18.500

10.  EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.

Authors:  Maiken Cavling Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope
Journal:  Mycoses       Date:  2014-01-13       Impact factor: 4.377

View more
  21 in total

1.  Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Authors:  Saad J Taj-Aldeen; Husam Salah; Winder B Perez; Muna Almaslamani; Mary Motyl; Atqah AbdulWahab; Kelley R Healey; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

3.  Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant Aspergillus Section Fumigati Clinical Isolates.

Authors:  S Dellière; L Verdurme; J Bigot; E Dannaoui; Y Senghor; F Botterel; A Fekkar; M E Bougnoux; C Hennequin; J Guitard
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values.

Authors:  A Espinel-Ingroff; J Turnidge; A Alastruey-Izquierdo; E Dannaoui; G Garcia-Effron; J Guinea; S Kidd; T Pelaez; M Sanguinetti; J Meletiadis; F Botterel; B Bustamante; Y-C Chen; A Chakrabarti; A Chowdhary; E Chryssanthou; S Córdoba; G M Gonzalez; J Guarro; E M Johnson; J V Kus; C Lass-Flörl; M J Linares-Sicilia; E Martín-Mazuelos; C E Negri; M A Pfaller; A M Tortorano
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates.

Authors:  B Carrara; R Richards; S Imbert; F Morio; M Sasso; N Zahr; A C Normand; P Le Pape; L Lachaud; S Ranque; D Maubon; R Piarroux; A Fekkar
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

6.  Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods.

Authors:  A Espinel-Ingroff; J Turnidge; A Alastruey-Izquierdo; F Botterel; E Canton; C Castro; Y-C Chen; Y Chen; E Chryssanthou; E Dannaoui; G Garcia-Effron; G M Gonzalez; N P Govender; J Guinea; S Kidd; M Lackner; C Lass-Flörl; M J Linares-Sicilia; L López-Soria; R Magobo; T Pelaez; G Quindós; M A Rodriguez-Iglesia; M A Ruiz; F Sánchez-Reus; M Sanguinetti; R Shields; P Szweda; A Tortorano; N L Wengenack; S Bramati; C Cavanna; C DeLuca; M Gelmi; A Grancini; G Lombardi; J Meletiadis; C E Negri; M Passera; J Peman; A Prigitano; E Sala; M Tejada
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

7.  Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

Authors:  A Luraschi; S Richard; P M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

8.  Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.

Authors:  Sarah Dellière; Kelley Healey; Maud Gits-Muselli; Bastien Carrara; Alessandro Barbaro; Nicolas Guigue; Christophe Lecefel; Sophie Touratier; Marie Desnos-Ollivier; David S Perlin; Stéphane Bretagne; Alexandre Alanio
Journal:  Front Microbiol       Date:  2016-12-23       Impact factor: 5.640

9.  Monitoring of clinical strains and environmental fungal aerocontamination to prevent invasive aspergillosis infections in hospital during large deconstruction work: a protocol study.

Authors:  Sophie Tiphaine Loeffert; Elise Melloul; Cédric Dananché; Laetitia Hénaff; Thomas Bénet; Pierre Cassier; Damien Dupont; Jacques Guillot; Françoise Botterel; Martine Wallon; Marie-Paule Gustin; Philippe Vanhems
Journal:  BMJ Open       Date:  2017-11-25       Impact factor: 2.692

10.  Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability.

Authors:  A Espinel-Ingroff; M Sasso; J Turnidge; M Arendrup; F Botterel; N Bourgeois; B Bouteille; E Canton; S Cassaing; E Dannaoui; M Dehais; L Delhaes; D Dupont; A Fekkar; J Fuller; G Garcia-Effron; J Garcia; G M Gonzalez; N P Govender; H Guegan; J Guinea; S Houzé; C Lass-Flörl; T Pelaez; A Forastiero; M Lackner; R Magobo
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.